Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Glycoprotein 41 pipeline drugs market research report outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.
Glycoprotein 41 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy area in the Glycoprotein 41 pipeline drugs market is infectious disease.
Glycoprotein 41 Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of action in the Glycoprotein 41 pipeline drugs market is Glycoprotein 41 Inhibitor.
Glycoprotein 41 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Glycoprotein 41 pipeline drugs market are intramuscular, oral, subcutaneous, intravenous, nasal, parenteral, topical, and vaginal.
Glycoprotein 41 Pipeline Drugs Market Analysis, by Routes of Administration
For more Glycoprotein 41 pipeline drugs routes of administration insights, download a free report sample
Glycoprotein 41 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Glycoprotein 41 pipeline drugs market are synthetic peptide, monoclonal antibody, subunit vaccine, recombinant peptide, recombinant protein, recombinant vector vaccine, small molecule, and vaccine.
Glycoprotein 41 Pipeline Drugs Market Analysis, by Molecule Types
For more Glycoprotein 41 pipeline drugs molecule type insights, download a free report sample
Competitive Landscape
Some of the leading companies in the Glycoprotein 41 pipeline drugs market are Frontier Biotechnologies Inc, Longevity Biotech Inc, MacroGenics Inc, Minka Therapeutics SA, Molecular Express Inc, Mymetics Corp, Navigen Inc, Novodux, Osel Inc, and Protheragen Inc.
Glycoprotein 41 Pipeline Drugs Market Analysis, by Companies
To know more about the Glycoprotein 41 pipeline drugs companies, download a free report sample
Glycoprotein 41 Pipeline Drugs Market Report Overview
Key Therapy Areas | Infectious Disease |
Key Mechanism of Actions | Glycoprotein 41 Inhibitor |
Key Routes of Administration | Intramuscular, Oral, Subcutaneous, Intravenous, Nasal, Parenteral, Topical, and Vaginal |
Key Molecule Types | Synthetic Peptide, Monoclonal Antibody, Subunit Vaccine, Recombinant Peptide, Recombinant Protein, Recombinant Vector Vaccine, Small Molecule, and Vaccine |
Leading Companies | Frontier Biotechnologies Inc, Longevity Biotech Inc, MacroGenics Inc, Minka Therapeutics SA, Molecular Express Inc, Mymetics Corp, Navigen Inc, Novodux, Osel Inc, and Protheragen Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41).
- Reviews of Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Longevity Biotech Inc
MacroGenics Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the Glycoprotein 41 pipeline drugs market?
The key therapy area in the Glycoprotein 41 pipeline drugs market is infectious disease.
-
What are the key mechanism of actions in the Glycoprotein 41 pipeline drugs market?
The key mechanism of action in the Glycoprotein 41 pipeline drugs market is Glycoprotein 41 Inhibitor.
-
What are the key routes of administration in the Glycoprotein 41 pipeline drugs market?
The key routes of administration in the Glycoprotein 41 pipeline drugs market are intramuscular, oral, subcutaneous, intravenous, nasal, parenteral, topical, and vaginal.
-
What are the key molecule types in the Glycoprotein 41 pipeline drugs market?
The key molecule types in the Glycoprotein 41 pipeline drugs market are synthetic peptide, monoclonal antibody, subunit vaccine, recombinant peptide, recombinant protein, recombinant vector vaccine, small molecule, and vaccine.
-
Which are the key companies in the Glycoprotein 41 pipeline drugs market?
The key companies in the Glycoprotein 41 pipeline drugs market are Frontier Biotechnologies Inc, Longevity Biotech Inc, MacroGenics Inc, Minka Therapeutics SA, Molecular Express Inc, Mymetics Corp, Navigen Inc, Novodux, Osel Inc, and Protheragen Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.